MX2025005318A - Compuesto de cucurbiturilo y uso medico del mismo - Google Patents

Compuesto de cucurbiturilo y uso medico del mismo

Info

Publication number
MX2025005318A
MX2025005318A MX2025005318A MX2025005318A MX2025005318A MX 2025005318 A MX2025005318 A MX 2025005318A MX 2025005318 A MX2025005318 A MX 2025005318A MX 2025005318 A MX2025005318 A MX 2025005318A MX 2025005318 A MX2025005318 A MX 2025005318A
Authority
MX
Mexico
Prior art keywords
compound
medical use
present disclosure
disclosure relates
cucurbituril compound
Prior art date
Application number
MX2025005318A
Other languages
English (en)
Inventor
Lingjian Zhu
Wenming Ren
Yang Zou
Shenghui Lei
Dan Zhu
Jian Huang
Original Assignee
Shanghai Senhui Medicine Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Senhui Medicine Co Ltd, Shanghai Shengdi Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Shanghai Senhui Medicine Co Ltd
Publication of MX2025005318A publication Critical patent/MX2025005318A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente descripción se refiere a un compuesto de cucurbiturilo y el uso médico del mismo. Específicamente, la presente descripción se refiere a un compuesto como se muestra en la fórmula (I), una sal farmacéuticamente aceptable del mismo, un método de preparación del mismo, una composición farmacéutica que comprende el mismo y el uso del mismo como un agente terapéutico, en particular el uso del mismo en el tratamiento o prevención de enfermedades proliferativas, enfermedades relacionadas con cardiovascular o cáncer de sangre y el uso del mismo en la reversión de bloqueo neuromuscular inducido por fármacos y/o anestesia, en donde cada sustituyente es como se define en la descripción. (I) (Ver Fórmula (I)).
MX2025005318A 2022-11-11 2025-05-07 Compuesto de cucurbiturilo y uso medico del mismo MX2025005318A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211412397 2022-11-11
CN202310888540 2023-07-19
PCT/CN2023/131007 WO2024099434A1 (zh) 2022-11-11 2023-11-10 葫芦脲类化合物及其医药用途

Publications (1)

Publication Number Publication Date
MX2025005318A true MX2025005318A (es) 2025-06-02

Family

ID=91031981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025005318A MX2025005318A (es) 2022-11-11 2025-05-07 Compuesto de cucurbiturilo y uso medico del mismo

Country Status (9)

Country Link
US (1) US20260167624A1 (es)
EP (1) EP4617274A4 (es)
JP (1) JP2025541968A (es)
KR (1) KR20250102033A (es)
CN (1) CN120019057A (es)
AU (1) AU2023378470A1 (es)
MX (1) MX2025005318A (es)
TW (1) TW202421155A (es)
WO (1) WO2024099434A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119613419A (zh) * 2023-09-13 2025-03-14 中国科学院上海有机化学研究所 氘代的二芳基甘脲四聚体化合物及其用途
WO2025237335A1 (zh) * 2024-05-14 2025-11-20 江苏恒瑞医药股份有限公司 一种葫芦脲衍生物的可药用盐、其结晶形式及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100400085B1 (ko) * 2001-07-04 2003-09-29 학교법인 포항공과대학교 수용성 및 지용성 쿠커비투릴 유도체, 그 제조방법, 그분리방법 및 용도
US9566351B2 (en) * 2010-10-13 2017-02-14 University Of Maryland, College Park Molecular containers and methods of making and using same
WO2012051407A2 (en) 2010-10-13 2012-04-19 University Of Maryland, College Park Molecular containers and methods of making and using same
EP3207046B1 (en) * 2014-10-18 2024-09-25 University of Maryland, College Park Acyclic cucurbit(n)uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders
WO2022206086A1 (zh) * 2021-04-19 2022-10-06 张振涛 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用
CN116925087A (zh) * 2023-07-18 2023-10-24 复旦大学 一类二芳基四甘脲羧酸盐及其用途
CN116925088A (zh) * 2023-07-21 2023-10-24 复旦大学 二芳并四甘脲八羧酸盐及其用途

Also Published As

Publication number Publication date
EP4617274A1 (en) 2025-09-17
US20260167624A1 (en) 2026-06-18
JP2025541968A (ja) 2025-12-24
TW202421155A (zh) 2024-06-01
CN120019057A (zh) 2025-05-16
KR20250102033A (ko) 2025-07-04
AU2023378470A1 (en) 2025-06-05
EP4617274A4 (en) 2026-03-18
WO2024099434A1 (zh) 2024-05-16

Similar Documents

Publication Publication Date Title
MX2025001700A (es) Compuestos triciclicos y uso medico de los mismos
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
CA2501651A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
CA2531862A1 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
EP2533785B1 (en) Treatment of loss of sense of touch with saxitoxin derivatives
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
AU2021311245A8 (en) Compound for androgen receptor degradation, and pharmaceutical use thereof
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
MX2025013245A (es) Compuesto de camptotecina deuterado, preparacion y uso de este
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
IL317168A (en) GCN2 modulator for cancer treatment
MX2025011458A (es) Inhibidor de cyp11a1 y uso del mismo
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
MX2024014994A (es) Macrociclos de indazol y su uso
MX2023014131A (es) Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo.
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
MX2023006193A (es) Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2022003845A (es) Tratamientos cognitivos medicinales.
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
MX2026002937A (es) Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos